Dutch biotech startup Cradle has recently made significant strides in the field of protein engineering. With a substantial investment of $24 million, the company is set to revolutionize the way proteins are designed and engineered using generative artificial intelligence (AI).
Cradle’s focus is on using generative AI to create proteins that extend beyond existing natural forms. They are currently engaged in various projects aimed at engineering diverse protein sequences and three-dimensional structures. These advancements have potential applications in multiple areas including enzyme production, vaccine development, lab-grown food, and other material sciences.
The power of generative AI
Generative AI has the potential to transform the field of biotechnology. It uses algorithms to generate new data by identifying patterns in existing datasets. This technology is particularly useful in areas such as drug discovery, protein engineering, diagnostics, and personalized medicine solutions.
Cradle’s approach
Cradle’s innovative approach treats the sequences of amino acids in human proteins as a programming language. This unique perspective has led them to integrate AI models into their work. While generative AI cannot yet create proteins with specific functions, it enables scientists to identify and select proteins suited for various conditions like room temperature stability or acidity.
Cradle’s proprietary AI, trained on billions of protein sequences and in-house laboratory data, is a game-changer. It assists biologists in designing superior proteins, accelerating R&D, and hastening drug development. Moreover, Cradle offers a web-based software solution that allows other companies to use their data for generative AI and machine learning tools.
Financial backing and partnerships
The Series A investment round saw contributions from Index Ventures, Kindred Capital, and notable individual investors. This funding brings Cradle’s total raised capital to $33 million. Founded in 2021 by a former Google AI Senior Product Manager, the company has already partnered with big names like Johnson & Johnson, Novozymes A/S, and Twist Bioscience.
Cradle is not alone in its pursuit. Evozyne, another deep learning biotech startup, recently closed an $81 million Series B funding round. The company focuses on AI-driven drug development, with algorithms that simulate protein evolution more efficiently than traditional methods.
The integration of AI into biotech is a growing trend that shows no signs of slowing down. As companies like Cradle and Evozyne continue to innovate, the potential for groundbreaking discoveries and advancements in the field becomes increasingly promising.
Cradle’s recent investment marks a significant milestone in the application of generative AI in biotechnology. With its innovative approach and the backing of influential investors, the company is well-positioned to lead the way in the evolving landscape of protein engineering and AI-driven biotechnology.
